The Bruker In-Vivo Multispectral FX PRO and In-Vivo Xtreme systems provide multimodal BLI, FLI, DRI, CLI (Cherenkov luminescense imaging), and X-ray imaging capabilities. These systems have been utilized in numerous preclinical oncology studies for in vivo tumor detection/monitoring and for the detection of cancer molecular markers. This review presents a set of representative preclinical oncology studies performed using the Bruker In-Vivo optical imaging systems. The selected studies used BL (e.g. firefly luciferase), FL (e.g. GFP, RFP, and NIR fluorophores), and/or DRI (e.g. 99mTc and 125I) reporters, and have advanced developments in tumor reporter systems and probes, cancer therapeutics, and have provided insights in to basic tumor biology. The note may also serve as a general primer to optical imaging methods and reporters used in preclinical oncology.